Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Trends in Prescribing Menopausal Hormone Therapy and Bisphosphonates in Australia and Manitoba, Canada and Adherence to Recommendations

dc.contributor.authorSalagame, Usha
dc.contributor.authorKliewer, Erich V
dc.contributor.authorDemers, Alain A
dc.contributor.authorBanks, Emily
dc.contributor.authorVelentzis, Louiza
dc.contributor.authorGoldsbury, David
dc.contributor.authorEgger, Sam
dc.contributor.authorLeslie, William D.
dc.contributor.authorCanfell, Karen
dc.date.accessioned2020-09-18T00:05:19Z
dc.date.issued2019
dc.date.updated2020-06-23T00:55:08Z
dc.description.abstractBackground: Recommendations for using menopausal hormone therapy (MHT) and bisphosphonates for postmenopausal osteoporosis management have changed over time. After the release of the Women’s Health Initiative (WHI) trial results in 2002, new evidence on risks and benefits of MHT became available, and newer guidelines generally specify that MHT should not be prescribed for prevention of chronic disease, including osteoporosis. This raises the question of whether bisphosphonate prescribing changed over time to compensate for the decrease in MHT use. Materials and Methods: We examined trends in dispensed prescriptions in Australia (national) and Canada (province of Manitoba) in relation to prescribing recommendations. Administrative data were used to describe dispensing patterns and changes for persons of all ages from 1996 to 2008, and for women aged 50 to ‡80 years from 2003 to 2008 in Australia and 1996 to 2008 in Canada. Results: In both geographic settings, MHT dispensing increased 1996–2001, peaked in 2001, and declined substantially thereafter (67% reduction in MHT prescriptions for Australia; 64% reduction for Manitoba, Canada to 2008). From 2003 to 2008, the number of MHT prescriptions declined among all age groups in both settings, with the highest declines among women in their 50s. Concurrently, bisphosphonate dispensing increased until 2005 (2001–2005: 260% increase in the number of prescriptions in Australia; 125% increase in Manitoba) and stabilized thereafter, in both settings. Annual bisphosphonate dispensing rates increased 4.1– 10.9% for women in their 70s and 80s in Australia and Manitoba during the period studied. Conclusions: Based on dispensed prescriptions data, more recent guidelines for MHT and bisphosphonates use for postmenopausal osteoporosis, which were updated during the study period (and are still consistent with the current guidelines), appear to have been broadly adhered to in both settings.en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn1931-843Xen_AU
dc.identifier.urihttp://hdl.handle.net/1885/210614
dc.language.isoen_AUen_AU
dc.publisherMary Ann Liebert Inc.en_AU
dc.rights© Mary Ann Liebert, Incen_AU
dc.sourceJournal of Women's Healthen_AU
dc.titleTrends in Prescribing Menopausal Hormone Therapy and Bisphosphonates in Australia and Manitoba, Canada and Adherence to Recommendationsen_AU
dc.typeJournal articleen_AU
local.bibliographicCitation.issue2en_AU
local.bibliographicCitation.lastpage186en_AU
local.bibliographicCitation.startpage177en_AU
local.contributor.affiliationSalagame, Usha, Cancer Council NSWen_AU
local.contributor.affiliationKliewer, Erich V, CancerCare Manitobaen_AU
local.contributor.affiliationDemers, Alain A, University of Manitobaen_AU
local.contributor.affiliationBanks, Emily, College of Health and Medicine, ANUen_AU
local.contributor.affiliationVelentzis, Louiza, Cancer Council NSWen_AU
local.contributor.affiliationGoldsbury , David , Cancer Research Division, Cancer Council New South Walesen_AU
local.contributor.affiliationEgger, Sam, Cancer Council NSWen_AU
local.contributor.affiliationLeslie, William D., University of Manitobaen_AU
local.contributor.affiliationCanfell, Karen, Cancer Counsil NSWen_AU
local.contributor.authoruidBanks, Emily, u4106314en_AU
local.description.embargo2037-12-31
local.description.notesImported from ARIESen_AU
local.identifier.absfor111711 - Health Information Systems (incl. Surveillance)en_AU
local.identifier.absseo920507 - Women's Healthen_AU
local.identifier.ariespublicationu3102795xPUB5595en_AU
local.identifier.citationvolume29en_AU
local.identifier.doi10.1089/jwh.2019.7828en_AU
local.identifier.thomsonIDWOS:000505210100001
local.publisher.urlhttps://home.liebertpub.com/publications/journal-of-womens-health/42en_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
01_Salagame_Trends_in_Prescribing_2019.pdf
Size:
409.91 KB
Format:
Adobe Portable Document Format
abcd